Globus pallidus degeneration and clinicopathological features of Huntington disease

Malvindar K Singh-Bains1,2, Lynette J Tippett1,3, Virginia M Hogg1,3

  • 1Centre for Brain Research, University of Auckland, Auckland, New Zealand.

Annals of Neurology
|June 4, 2016
PubMed

Insights

Huntington disease (HD) causes significant neurodegeneration in the globus pallidus (GP), particularly the GPe and VP, impacting cognition and motor function. The GPi is less affected, with degeneration linked to irritability.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Genetics

Background:

  • Huntington disease (HD) is characterized by striatal neurodegeneration.
  • The globus pallidus (GP), a key output nucleus of the striatum, has been less studied in HD.
  • Understanding GP degeneration is crucial for a comprehensive view of HD pathology.

Purpose of the Study:

  • To investigate neurodegeneration patterns in three subdivisions of the human globus pallidus (GP) in Huntington disease (HD).
  • To correlate GP degeneration with clinical symptomatology and striatal neuropathological grade.

Main Methods:

  • Stereology was employed to quantify regional atrophy, neuronal loss, and soma atrophy.
  • The study compared 8 HD cases with 7 matched controls.
  • Measurements were taken in the external (GPe), internal (GPi), and ventral pallidum (VP).

Main Results:

  • The GPe exhibited significant atrophy (54% volume loss) and neuron loss (60%).
  • The VP showed substantial degeneration (31% volume loss, 48% neuron loss).
  • The GPi was less affected, with a 38% volume reduction; degeneration correlated with irritability.

Conclusions:

  • The Huntington disease (HD) gene mutation leads to differential degeneration in globus pallidus (GP) segments.
  • GP degeneration severity correlates with striatal neuropathological grade.
  • Pallidal degeneration is linked to specific clinical symptoms, offering insights into HD clinicopathology.
Abstract

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K